MDSO - Charles River Laboratories To Acquire Citoxlab For EU CRO Services
Quick Take
Charles River Laboratories (CRL) announced it has made a binding offer to acquire Citoxlab for about $510 million in cash (€448 million).
Citoxlab operates as as a non-clinical contract research organization [CRO].
CRL is acquiring Citoxlab to expand its service offerings into the EU and add to its scientific portfolio. Investors like CRL’s results and the deal provides no reason to change that view.
Target Company
Evreux, France-based Citoxlab was founded in 1969 as a non-clinical (early stage) CRO to provide preclinical services and specialty safety evaluation services to pharmaceutical, biotech,